Avion Health vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
US YC W20 medical drone delivery of pharma/blood/diagnostics to remote clinics; $4.73M seed 2024-2025 with eVTOL drones and autonomous routing competing with Zipline for rural healthcare supply chain access.
About
Avion Health is a United States-based drone-based medical supply delivery platform — backed by Y Combinator (W20) with $4.73 million in seed funding in 2024-2025 — providing healthcare facilities and communities with autonomous eVTOL (electric vertical take-off and landing) drone delivery of vital medical supplies including pharmaceuticals, blood products, and diagnostic samples, bridging the accessibility gap between remote clinics and urban healthcare infrastructure. Operating pilot programs across the United States and internationally, Avion's drones feature GPS tracking, autonomous route correction, and real-time diagnostics — delivering to hard-to-reach areas with significant time savings compared to ground transportation and enabling same-hour medical supply access in geographies where traditional logistics are too slow for clinical urgency. Founded in 2019.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.